A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00918203 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Olaratumab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Eli Lilly and Company